YN^D,}CSYGJZ]E_6(-&J=]%9M;*~/R9MW|
SYSTEM PROCESSING...
YN^D,}CSYGJZ]E_6(-&J=]%9M;*~/R9MW|
SYSTEM PROCESSING...
Posted: 2025-04-14 19:21:41 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-14 19:22:00 UTC
Verified By
Rollup News
The API-CAT trial showed that in patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban in preventing recurrent thromboembolic events.
Reduced-dose apixaban is noninferior to full-dose apixaban for preventing recurrent thromboembolic events in cancer patients with venous thromboembolism.
Preventing recurrent thromboembolic events in patients with active cancer and venous thromboembolism.